Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, SpainClara Mazagatos, Mercedes Rumayor, Virtudes Gallardo García et al.|Influenza and Other Respiratory Viruses|2024Cited by 25
Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023–January 2024Charlotte Lanièce Delaunay, Esther Kissling, Ivan Mlinarić et al.|Vaccine|2024Cited by 24
Severity of respiratory syncytial virus compared with SARS-CoV-2 and influenza among hospitalised adults ≥65 yearsLorena Vega-Piris, Susana Monge, José Luis Mayordomo et al.|Journal of Infection|2024Cited by 17
Effectiveness of Covid-19 Vaccines Administered in the 2023 Autumnal Campaigns in Europe: Results from the Vebis Primary Care Test-Negative Design Study, September 2023–January 2024Charlotte Lanièce Delaunay, Esther Kissling, Aryse Melo et al.|SSRN Electronic Journal|2024Cited by 0
Author response for "Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain"Clara Mazagatos, The SARI Sentinel Surveillance RSV Study Group, Jacobo Mendioroz et al.|Unknown|2024Cited by 0